AR071794A1 - Anticuerpos anti-fn14 (factor de necrosis) que inducen la muerte de celulas tumorales, y sus usos - Google Patents
Anticuerpos anti-fn14 (factor de necrosis) que inducen la muerte de celulas tumorales, y sus usosInfo
- Publication number
- AR071794A1 AR071794A1 ARP090101740A ARP090101740A AR071794A1 AR 071794 A1 AR071794 A1 AR 071794A1 AR P090101740 A ARP090101740 A AR P090101740A AR P090101740 A ARP090101740 A AR P090101740A AR 071794 A1 AR071794 A1 AR 071794A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- induce
- tumor cells
- necrosis factor
- destruction
- Prior art date
Links
- 230000034994 death Effects 0.000 title abstract 2
- 210000004881 tumor cell Anatomy 0.000 title abstract 2
- 230000017074 necrotic cell death Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 abstract 1
- 102000016946 TWEAK Receptor Human genes 0.000 abstract 1
- 108010014401 TWEAK Receptor Proteins 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Adem s la presente solicitud se refiere a anticuerpos y fragmentos de anticuerpos que se unen al receptor Fn14 e inducen o aumentan la destruccion de celulas cancer¡genas que expresan Fn14. Asimismo la presente solicitud se refiere a composiciones farmaceuticas que comprenden dichos anticuerpos as¡ como metodos para usar los anticuerpos y fragmentos de anticuerpos para inducir la muerte de una celula tumoral y tratar trastornos en un sujeto. Reivindicacion 1: Un anticuerpo aislado, o fragmento de union a ant¡geno de este, que (i) se une selectivamente al polipeptido de la SEC. ID. Ns 1, cuando se expresa sobre la superficie de una celula, en un ep¡tope que incluye el residuo de amino cido triptofano en la posicion 42 de SEC. ID Ns 1, y (ii) induce o aumenta la destruccion de celulas cancer¡genas in vivo o in vitro.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5365008P | 2008-05-15 | 2008-05-15 | |
| US14951709P | 2009-02-03 | 2009-02-03 | |
| US17313709P | 2009-04-27 | 2009-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071794A1 true AR071794A1 (es) | 2010-07-14 |
Family
ID=41319269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101740A AR071794A1 (es) | 2008-05-15 | 2009-05-14 | Anticuerpos anti-fn14 (factor de necrosis) que inducen la muerte de celulas tumorales, y sus usos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090324602A1 (es) |
| EP (1) | EP2294089A2 (es) |
| JP (1) | JP2011523414A (es) |
| AR (1) | AR071794A1 (es) |
| AU (1) | AU2009246640A1 (es) |
| BR (1) | BRPI0912198A2 (es) |
| CA (1) | CA2723973A1 (es) |
| IL (1) | IL209309A0 (es) |
| MX (1) | MX2010012324A (es) |
| TW (1) | TW201008579A (es) |
| WO (1) | WO2009140177A2 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1387538A (zh) | 1999-01-15 | 2002-12-25 | 比奥根公司 | 针对tweak及tweak受体的拮抗剂和它们在治疗免疫性疾病中的应用 |
| US7208151B2 (en) * | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| WO2003086311A2 (en) * | 2002-04-09 | 2003-10-23 | Biogen, Inc. | Methods for treating tweak-related conditions |
| DK2529619T3 (en) | 2005-02-17 | 2016-01-11 | Biogen Ma Inc | Treatment of neurological disorders |
| EP1885388B1 (en) | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Treating and evaluating inflammatory disorders |
| WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| EP2350271B1 (en) | 2008-11-20 | 2016-01-27 | Biogen MA Inc. | Arginine inactivation of enveloped viruses |
| US9005926B2 (en) | 2009-10-02 | 2015-04-14 | Biogen Idec Ma Inc. | Methods of preventing and removing trisulfide bonds |
| US9068004B2 (en) | 2010-02-04 | 2015-06-30 | University Of Louisville Research Foundation, Inc. | TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| US8609818B2 (en) * | 2011-03-10 | 2013-12-17 | Omeros Corporation | Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
| EP3388443A1 (en) | 2011-05-13 | 2018-10-17 | Biogen MA Inc. | Methods of preventing and removing trisulfide bonds |
| JP2014529597A (ja) | 2011-08-23 | 2014-11-13 | トランスバイオ リミテッド | Ｆｎ１４結合性タンパク質及びその使用 |
| WO2013177386A1 (en) * | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
| AU2014280174A1 (en) | 2013-06-14 | 2015-12-03 | Bayer Pharma Aktiengesellschaft | Anti-TWEAKR antibodies and uses thereof |
| US20160223547A1 (en) | 2013-09-13 | 2016-08-04 | Angels SIERRA JIMÉNLEZ | Marker for predicting metastasis of breast cancer |
| BR112016014830A2 (pt) | 2013-12-23 | 2017-09-19 | Bayer Pharma AG | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp |
| EP3209697A4 (en) * | 2014-10-23 | 2018-05-30 | La Trobe University | Fn14-binding proteins and uses thereof |
| EP3233127A1 (de) * | 2014-12-15 | 2017-10-25 | Bayer Pharma Aktiengesellschaft | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern |
| CN108025084A (zh) | 2015-06-22 | 2018-05-11 | 拜耳医药股份有限公司 | 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc） |
| EP3313521A1 (de) | 2015-06-23 | 2018-05-02 | Bayer Pharma Aktiengesellschaft | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern |
| WO2016207104A1 (de) * | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern |
| JP2018528161A (ja) | 2015-06-23 | 2018-09-27 | バイエル ファーマ アクチエンゲゼルシャフト | Ｋｓｐ阻害剤との部位特異的均一複合体 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| MX2018011627A (es) | 2016-03-24 | 2019-01-10 | Bayer Pharma AG | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles. |
| WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| EP3558386A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| MX2019007641A (es) | 2016-12-21 | 2019-09-09 | Bayer Pharma AG | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. |
| JP2021512103A (ja) | 2018-01-31 | 2021-05-13 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｎａｍｐｔ阻害剤を含む抗体薬物複合体（ａｄｃｓ） |
| CN112368299A (zh) * | 2018-04-02 | 2021-02-12 | 阿拉玛布治疗学股份有限公司 | 连接蛋白43抗体及其用途 |
| CN112930195B (zh) * | 2018-10-31 | 2024-03-19 | 安斯泰来制药株式会社 | 抗人Fn14抗体 |
| CA3124356A1 (en) * | 2018-12-20 | 2020-06-25 | Kyowa Kirin Co., Ltd. | Fn14 antibodies and uses thereof |
| US20220411494A1 (en) * | 2019-02-04 | 2022-12-29 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| CN112979760B (zh) * | 2021-04-21 | 2023-09-29 | 华侨大学 | 一种肝星状细胞受体Fn14的特异靶向功能肽及其应用 |
| WO2024105206A1 (en) | 2022-11-17 | 2024-05-23 | Vincerx Pharma Gmbh | Antibody-drug-conjugates cleavable in a tumor microenvironment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006125632A2 (en) * | 2005-05-24 | 2006-11-30 | Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh | Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy |
| KR20100053607A (ko) * | 2007-08-03 | 2010-05-20 | 패시트 바이오테크 코포레이션 | 항-ｔｗｅａｋ 수용체 항체의 치료 용도 |
-
2009
- 2009-05-08 US US12/463,291 patent/US20090324602A1/en not_active Abandoned
- 2009-05-08 BR BRPI0912198A patent/BRPI0912198A2/pt not_active IP Right Cessation
- 2009-05-08 AU AU2009246640A patent/AU2009246640A1/en not_active Abandoned
- 2009-05-08 MX MX2010012324A patent/MX2010012324A/es not_active Application Discontinuation
- 2009-05-08 CA CA2723973A patent/CA2723973A1/en not_active Abandoned
- 2009-05-08 JP JP2011509580A patent/JP2011523414A/ja not_active Ceased
- 2009-05-08 EP EP09736321A patent/EP2294089A2/en not_active Withdrawn
- 2009-05-08 WO PCT/US2009/043382 patent/WO2009140177A2/en active Application Filing
- 2009-05-14 TW TW098116062A patent/TW201008579A/zh unknown
- 2009-05-14 AR ARP090101740A patent/AR071794A1/es unknown
-
2010
- 2010-11-15 IL IL209309A patent/IL209309A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009140177A3 (en) | 2010-08-26 |
| WO2009140177A2 (en) | 2009-11-19 |
| US20090324602A1 (en) | 2009-12-31 |
| BRPI0912198A2 (pt) | 2019-09-24 |
| CA2723973A1 (en) | 2009-11-19 |
| IL209309A0 (en) | 2011-01-31 |
| TW201008579A (en) | 2010-03-01 |
| AU2009246640A1 (en) | 2009-11-19 |
| JP2011523414A (ja) | 2011-08-11 |
| EP2294089A2 (en) | 2011-03-16 |
| MX2010012324A (es) | 2011-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071794A1 (es) | Anticuerpos anti-fn14 (factor de necrosis) que inducen la muerte de celulas tumorales, y sus usos | |
| DOP2014000083A (es) | Inmunoenlazadores dirigidos contra el tnf | |
| PE20120569A1 (es) | Proteinas de union especificas y sus usos | |
| GT200600389A (es) | Polipeptidos y anticuerpos | |
| BR0316092A (pt) | Anticoprpos de domìnio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos | |
| AR076195A1 (es) | Anticuerpos biespecificos anti-erbb-1/anti-c-met | |
| AR072749A1 (es) | Anticuerpos contra receptor del factor de la necrosis tumoral (baffr) y composiciones farmaceuticas | |
| AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| WO2009085216A3 (en) | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease | |
| CL2008003527A1 (es) | Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7 | |
| CL2012003283A1 (es) | Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8. | |
| CL2011000230A1 (es) | Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado. | |
| CU20120095A7 (es) | Antagonistas de pcsk9 | |
| PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| AR059809A1 (es) | Anticuerpos anti-5t4 y sus usos | |
| PE20131376A1 (es) | Anticuerpos para metaloproteinasa-9 de matriz | |
| CO6390041A2 (es) | Agentes y antagonistas fijaodres de notch y metodos para el uso de los mismos. | |
| ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| AR080158A1 (es) | Anticuerpos contra el receptor de la muerte 5 | |
| DOP2013000045A (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| CO6220870A2 (es) | Prediccion de respuesta a un inhibidor a un inhibidor de dimerizacion her basado en expresion de her3 bajo | |
| NO20081987L (no) | Humane, monoklonale antistoffer mot CD70 | |
| AR064109A1 (es) | Anticuerpos humanos que se enlazan al cd22 y sus usos | |
| ECSP099341A (es) | Nuevos anticuerpos antiproliferativos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |